CLOPITAB CV 20 TAB

Description

CLOPITAB CV 20 TAB is a cardiovascular combination tablet containing Clopidogrel and Aspirin. This formulation offers dual antiplatelet therapy by inhibiting platelet aggregation through two complementary mechanisms. Clopidogrel selectively blocks the ADP receptor on platelets, while Aspirin irreversibly inhibits the cyclooxygenase (COX) enzyme, reducing thromboxane A2 production, a key factor in platelet activation.

This combination is commonly prescribed for patients with acute coronary syndrome, recent myocardial infarction, ischemic stroke, or those who have undergone coronary stenting. The dual-action reduces the risk of thrombotic cardiovascular events by preventing harmful blood clots and maintaining healthy blood flow.

Patients should take CLOPITAB CV 20 TAB as directed by their healthcare provider and report any unusual bleeding or side effects promptly. Due to the increased risk of bleeding, careful monitoring is recommended during therapy.